WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsZimmer Biomet Holdings Inc (ZBH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 151% more annual revenue ($20.63B vs $8.23B). GEHC leads profitability with a 10.1% profit margin vs 8.6%. ZBH appears more attractively valued with a PEG of 0.60. GEHC earns a higher WallStSmart Score of 60/100 (C+).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

ZBH

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 5.5Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued
ZBHSignificantly Overvalued (-296.1%)

Margin of Safety

-296.1%

Fair Value

$24.14

Current Price

$87.64

$63.50 premium

UndervaluedFair: $24.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

ZBH2 strengths · Avg: 9.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

PEG RatioValuation
0.608/10

Growing faster than its price suggests

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

ZBH3 concerns · Avg: 2.7/10
Return on EquityProfitability
5.6%3/10

ROE of 5.6% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-40.8%2/10

Earnings declined 40.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : ZBH

The strongest argument for ZBH centers on Price/Book, PEG Ratio. Revenue growth of 10.9% demonstrates continued momentum. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : ZBH

The primary concerns for ZBH are Return on Equity, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

GEHC carries more volatility with a beta of 1.18 — expect wider price swings.

ZBH is growing revenue faster at 10.9% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GEHC scores higher overall (60/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Zimmer Biomet Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.

Visit Website →

Want to dig deeper into these stocks?